By Rishika Sadam HYDERABAD (Reuters) -Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new analysis finds. Newer medications, such as Mounjaro and Wegovy, exhibit both ...

There continues to be “pent up demand” for Wegovy, but Novo Nordisk expects this to become less of a problem as more supply of the drug becomes available over the next few months, Jorgensen said.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Modern weight loss medications represent a breakthrough, but they are most effective when combined with the right lifestyle strategies. Here's what that looks like.

Discover the weight loss results of Novo Nordisk's phase 3 trial for Wegovy injections, with participants losing an average of 18.7% of their body weight.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

In addition, nearly 32% of people taking Zepbound lost at least a quarter of their body weight, compared to about 16% of those taking Wegovy, the study found. Weight loss was about 6% lower in men ...

Zepbound led to an average weight loss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study’s findings, what sets these drugs apart and ...